Oppenheimer downgraded Sutro Biopharma (STRO) to Perform from Outperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls
- Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler
- Sutro Biopharma double downgraded at BofA after luvelta deprioritized
- Sutro Biopharma downgraded to Underperform from Buy at BofA